Mining tool company Globaltech has lost its bid to delay Australian Mud Company’s case, on foot since 2016, which seeks $39.9 million in damages for its rival’s infringement of a mining tool patent.
The maker of Mother brand energy drinks has won a stay of a judge’s decision to remove one of its trade marks for non-use, but has been hit with indemnity costs in its ongoing intellectual property stoush with rival Cantarella Bros.
The High Court has agreed to weigh in on whether property data analytics firm CoreLogic infringed a real estate photographer’s copyright by uploading images from realestate.com.au to its platform.
An Australian designer of a trendy neoprene handbag sold at high-end department stores has lost an appeal which challenged a judge’s finding that its flagship bag was not a work of artistic craftsmanship.
Mills Oakley has bolstered its intellectual property practice with the appointment of new partner Lisa Egan, who will be based in the firm’s Melbourne office.
The Full Court has overturned a landmark judgment which found artificial intelligence can be named as an inventor on patent applications, in a decision which brings Australia in line with findings from courts in the UK, US and EU.
Maurice Blackburn has successfully defeated an appeal of a judgment that found the law firm did not breach the intellectual property rights of US financial services giant State Street Global Advisors by displaying a replica of the world renowned Fearless Girl statue in Melbourne.
Kmart Australia and toy manufacturer Headstart International have hit back at Jellycat in a suit claiming they are selling ‘Bashful Bunny’ knockoffs, arguing the shape and features of the popular plush rabbit are not exclusive to the London-based soft toy designer.
The Full Federal Court won’t give Swiss pharmaceuticals giant Novartis the chance to appeal a ruling that threw out three of its four experts in a patent case against generic drug maker Pharmacor.
The competition regulator has proposed to deny authorisation for a patent settlement that sought to permit early entry of generic drugs. Whether the companies involved will be able to quell the ACCC’s concerns remains to be seen, but what is clear is that future authorisation applications will contend with significant forensic challenges, writes Corrs Chambers Westgarth’s Odette Gourley, Richard Flitcroft, David Fixler and Ian Reynolds.